Interpretation of Clinical Guideline for Anti-vascular Endothelial Growth Factor Therapy of Retinopathy of Prematurity by Japanese Ophthalmological Society
10.3760/cma.j.cn115989-20210520-00313
- VernacularTitle:日本眼科学会《早产儿视网膜病变的抗VEGF疗法临床指南》解读
- Author:
Xiaoyuan YANG
1
;
Yuting CAI
;
Yun LI
Author Information
1. 中南大学湘雅二医院眼科 湖南省眼科临床医学研究中心，长沙 410011
- Keywords:
Retinopathy of prematurity;
Clinical guideline;
Interpretation;
Anti-vascular endothelial growth factor treatment
- From:
Chinese Journal of Experimental Ophthalmology
2021;39(11):1003-1009
- CountryChina
- Language:Chinese
-
Abstract:
Retinopathy of prematurity (ROP) is the leading cause of blindness in children worldwide.Intravitreal injection of anti-vascular endothelial growth factor (VEGF) has become a widely used first-line treatment for ROP in recent decade, but the anti-VEGF treatment of ROP is off-label in China, and the injection method and dosage are different from adults.In December 2020, the Clinical Guideline for Anti-vascular Endothelial Growth Factor Therapy of Retinopathy of Prematurity was released by the Japanese Ophthalmological Society, which is by far the only guideline for anti-VEGF treatment of ROP.Due to the ethnic similarity between Japanese and Chinese, this guideline is of high reference value to Chinese ROP clinical practice.This article introduced and interpreted the main information in the guideline to provide Chinese ophthalmologists references for the understanding, diagnosis and treatment of ROP.
